Everpar Advisors LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,021 shares of the company’s stock, valued at approximately $229,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Insight Wealth Strategies LLC raised its holdings in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares during the period. Cerity Partners LLC boosted its stake in shares of Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after acquiring an additional 3,610 shares during the period. Portfolio Design Labs LLC acquired a new position in shares of Cencora during the 3rd quarter worth approximately $1,404,000. Mackenzie Financial Corp raised its stake in Cencora by 9.9% in the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock valued at $18,250,000 after acquiring an additional 7,266 shares during the period. Finally, Nordea Investment Management AB boosted its position in Cencora by 40.2% during the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock worth $243,173,000 after purchasing an additional 308,773 shares during the period. 97.52% of the stock is owned by institutional investors.
Cencora Stock Performance
NYSE COR opened at $242.11 on Friday. The firm’s 50 day simple moving average is $237.52 and its 200 day simple moving average is $233.85. The firm has a market capitalization of $46.80 billion, a price-to-earnings ratio of 32.24, a P/E/G ratio of 1.48 and a beta of 0.49. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27.
Cencora Increases Dividend
Insider Activity at Cencora
In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 over the last ninety days. 15.80% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
COR has been the subject of a number of research reports. Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Wells Fargo & Company decreased their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Robert W. Baird boosted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.60.
Cencora Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
- Five stocks we like better than Cencora
- What is the FTSE 100 index?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- 3 Healthcare Dividend Stocks to Buy
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- ETF Screener: Uses and Step-by-Step Guide
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.